Truist Financial Lowers ICON Public (NASDAQ:ICLR) Price Target to $262.00

ICON Public (NASDAQ:ICLR) had its price target decreased by equities researchers at Truist Financial from $284.00 to $262.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Truist Financial’s price target suggests a potential upside of 41.47% from the stock’s previous close.

Other equities research analysts also recently issued reports about the stock. Citigroup reduced their price target on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Robert W. Baird reduced their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. JPMorgan Chase & Co. cut their price target on ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Finally, Baird R W cut shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $283.92.

ICON Public Stock Performance

Shares of ICLR opened at $185.20 on Thursday. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72. The company has a 50-day simple moving average of $206.00 and a 200-day simple moving average of $251.32. The company has a market capitalization of $15.28 billion, a PE ratio of 20.65, a P/E/G ratio of 1.78 and a beta of 1.19.

Institutional Trading of ICON Public

A number of hedge funds have recently bought and sold shares of ICLR. Sierra Ocean LLC acquired a new stake in shares of ICON Public during the fourth quarter worth $29,000. Park Place Capital Corp lifted its position in ICON Public by 281.4% during the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after buying an additional 166 shares during the period. Private Trust Co. NA boosted its stake in ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after buying an additional 82 shares during the last quarter. GAMMA Investing LLC grew its holdings in ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after buying an additional 169 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in shares of ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after acquiring an additional 96 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.